DT MedTech, LLC
The H3 TAR Prosthesis was approved by FDA (P160036) on June 4, 2019. Continued approval of the premarket approval application (PMA) is contingent upon the submission of periodic reports (Annual Report), required under 21 CFR 814.84. In order to provide continued reasonable assurance of the safety and effectiveness of the PMA device, data from this post-approval study must be submitted to FDA in a PMA Post-Approval Study Report per the requirements set forth in the approval.
Osteoarthritis Ankle
Post-Traumatic Osteoarthritis of Ankle
Osteoarthritis of Ankle Secondary to Inflammatory Arthritis (Disorder)
Hintermann Series H3 Total Ankle Replacement System
NA
The Hintermann Series H3® (H3) prosthesis is a mobile bearing total ankle replacement (TAR) indicated for use as a non-cemented implant to replace a painful arthritic ankle joint due to primary osteoarthritis, post-traumatic osteoarthritis or arthritis secondary to inflammatory disease (e.g., rheumatoid arthritis, hemochromatosis, etc.). The present version (third generation) of the H3 TAR and the earlier generations of this total ankle system have been marketed (initially in 2003) under a license agreement in Europe, South Korea, Australia, and Canada and other countries outside the U.S. (OUS). The H3 TAR prosthesis has been used in over 20,000 procedures in the markets OUS. The H3 TAR device has not been withdrawn from marketing for any reason. The H3 TAR Prosthesis was approved by FDA (P160036) on June 4, 2019. Continued approval of the premarket approval application (PMA) is contingent upon the submission of periodic reports (Annual Report), required under 21 CFR 814.84. In order to provide continued reasonable assurance of the safety and effectiveness of the PMA device, data from this post-approval study must be submitted to FDA in a PMA Post-Approval Study Report per the requirements set forth in the approval.
Study Type : | INTERVENTIONAL |
Estimated Enrollment : | 232 participants |
Masking : | NONE |
Primary Purpose : | TREATMENT |
Official Title : | Post Approval Study 2: Hintermann Series H3 Total Ankle Replacement System |
Actual Study Start Date : | 2022-02-01 |
Estimated Primary Completion Date : | 2029-04 |
Estimated Study Completion Date : | 2029-04 |
Information not available for Arms and Intervention/treatment
Ages Eligible for Study: | 21 Years |
Sexes Eligible for Study: | ALL |
Accepts Healthy Volunteers: | 1 |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
RECRUITING
Los Angeles Institute of Foot and Ankle Surgery
Mission Hills, California, United States, 91345
RECRUITING
Florida Orthopedic Foot & Ankle Center
Sarasota, Florida, United States, 34233
RECRUITING
Paley Orthopedic & Spine Institute
West Palm Beach, Florida, United States, 33407
RECRUITING
Orthopaedic Associates
Evansville, Indiana, United States, 47710
RECRUITING
Department of Orthopedic Surgery, Johns Hopkins Outpatient Center
Baltimore, Maryland, United States, 21287
RECRUITING
New Mexico Bone and Joint Institute
Alamogordo, New Mexico, United States, 88310
RECRUITING
Duke Orhtopaedics Arringdon
Morrisville, North Carolina, United States, 27560
TERMINATED
Dept. of Orthopedic Surgery and Rehabilitation, University of Oklahoma
Oklahoma City, Oklahoma, United States, 73104
RECRUITING
MUSC Department of Orthopaedics/Foot and Anke Services
Charleston, South Carolina, United States, 29425
RECRUITING
Spring Branch Podiatry, PLLC
Houston, Texas, United States, 77024